Narcolepsy: A clinical review

Practical Neurology

Volumn 14, Issue 5, 2014, Pages 323-331

  Leschziner, Guy ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MANAGEMENT; HUMAN; NARCOLEPSY;

DISEASE MANAGEMENT; HUMANS; NARCOLEPSY;

EID: 84907011506     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/practneurol-2014-000837     Document Type: Review

References (40)

1. Yoss RE, Daly DD. Criteria for the diagnosis of the narcoleptic syndrome. Proc Staff Meet Mayo Clin 1957;32:320–8.
2. Vogel G. Studies in psychophysiology of dreams III. The dream of narcolepsy. Arch Gen Psychiatry 1960;3:421–8.
3. Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998;50:S16–22.
4. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011;70:410–17.
5. Aran A, Lin L, Nevsimalova S, et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009;32:979–83.
6. Cvetkovic-Lopes V, Bayer L, Dorsaz S, et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 2010;120:713–19.
7. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365–76.
8. Thannickal TC, Moore RY, Nienhuis R, et al. Reduced number of hypocretin neurons in human narcolepsy. Neurone 2000;27:469–74.
9. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000;6:991–7.
10. Luppi PH, Clement O, Sapin E, et al. The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behaviour disorder. Sleep Med Rev 2011;15:153–63.
11. Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations in France and Quebec. Neurology 2001;57:2029–33.
12. International Classification of Sleep Disorders. Diagnostic and coding manual. 2nd edn. Westchester, IL, USA: American Academy of Sleep Medicine, 2005.
13. Sturzenegger C, Bassetti CL. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res 2004;13:395–406.
14. Lammers GJ, Overeem S, Tijssen MA, et al. Effects of startle and laughter in cataplectic subjects: a neurophysiological study between attacks. Clin Neurophysiol 2000;111:1276–81.
15. Pedroso JL, Fusao EF, Ladeia-Frota C, et al. Gelastic cataplexy as the first neurologic manifestation of Niemann-Pick type C. Neurology 2012;79:e189.
16. Dreissen YE, Tijssen MA. The starle syndromes: physiology and treatment. Epilepsia 2012;53(S7):3–11.
17. Nelson GB, Hahn JS. Stimulus-induced drop episodes in Coffin-Lowry syndrome. Pediatrics 2003;111:e197–202.
18. Shankar R, Jalihal V, Walker M, et al. Pseudocataplexy and transient functional paralysis: a spectrum of psychogenic motor disorder. J Neuropsychiatry Clin Neurosci 2010;22:445–50.
19. Nightingale S, Orgill JC, Ebrahim IO, et al. The association between narcolepsy and REM behaviour disorder. Sleep Med 2005;6:253–8.
20. Naumann A, Bellebaum C, Daum I. Cognitive deficits in narcolepsy. J Sleep Res 2006;15:329–38.
21. Ohayon MM. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep Med 2013;14:488–92.
22. Buskova J, Klaschka J, Sonka K, et al. Olfactory dysfunction in narcolepsy with and without cataplexy. Sleep Med 2010;11:558–61.
23. Sonka K, Kemlink D, Buskova J, et al. Obesity accompanies narcolepsy with cataplexy but not narcolepsy without cataplexy. Neuro Endocrinol Lett 2010;31:631–4.
24. Donjacour CE, Pardi D, Aziz NA, et al. Plasma total ghrelin and leptin levels in human narcolepsy and matched healthy controls: basal concentrations and response to sodium oxybate. J Clin Sleep Med 2013;9:797–803.
25. Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005;9:269–310.
26. Tsutsui K, Kanbayashi T, Tanaka K, et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia and narcolepsy with psychotic features. BMC Psychiatry 2012;8:12–37.
27. Haq IZ, Naidu Y, Reddy P, et al. Narcolepsy in Parkinson’s disease. Expert Rev Neurother 2010;10:879–84.
28. Mignot E, Lin L, Finn L, et al. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain 2006;129:1609–23.
29. Aldrich MS, Chervin RD, Malow BA. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997;20:620–9.
30. Drakatos P, Suri A, Higgins SE, et al. Sleep stage sequence of sleep onset REM periods in the hypersomnias. J Neurol Neurosurg Psychiatry 2013;84:223–7.
31. Drakatos P, Kosky CA, Higgins SE, et al. First rapid eye movement sleep periods and sleep-onset rapid eye movement periods in sleep-stage sequencing of hypersomnias. Sleep Med 2013;14:897–901.
32. Bourgin P, Zeitzer JM, Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol 2008;7:649–62.
33. Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness. Neurology 1997;49:444–51.
34. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011;306:2673–83.
35. Plazzi G, Poli F, Franceschini C, et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol 2008;255:1549–54.
36. Valko PO, Khatami R, Baumann CR, et al. No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy. J Neurol 2008;255:1900–3.
37. Mieda M, Sakurai T. Orexin (hypocretin) receptor agonists and antagonists for treatment of sleep disorders. Rationale for development and current status. CNS Drugs 2013;27:83–90.
38. De la Herran-Arita AK, Garcia-Garcia F. Current and emerging options for the drug treatment of narcolepsy. Drugs 2013;73:1771–81.
39. Thebault S, Vincent A, Gringras P. Narcolepsy and H1N1 vaccination: a link? Curr Opin Pulm Med 2013;19:587–93.
40. De la Herran-Arita AK, Kornum BR, Mahlios J, et al. CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med 2013;5:216ra176.